Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 1
1965 2
1966 4
1967 3
1968 7
1969 3
1970 1
1971 2
1972 6
1973 2
1974 3
1975 3
1977 6
1979 2
1980 2
1981 2
1982 3
1983 1
1984 1
1985 2
1986 8
1987 1
1988 4
1989 4
1990 5
1992 5
1993 3
1994 3
1996 2
1997 1
1999 6
2000 3
2001 2
2003 2
2004 1
2005 4
2006 8
2007 5
2008 3
2009 6
2010 7
2011 5
2012 8
2013 9
2014 16
2015 17
2016 17
2017 16
2018 23
2019 16
2020 23
2021 13
2022 18
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: lakshmanan m. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.
Rialdi A, Duffy M, Scopton AP, Fonseca F, Zhao JN, Schwarz M, Molina-Sanchez P, Mzoughi S, Arceci E, Abril-Fornaguera J, Meadows A, Ruiz de Galarreta M, Torre D, Reyes K, Lim YT, Rosemann F, Khan ZM, Mohammed K, Wang X, Yu X, Lakshmanan M, Rajarethinam R, Tan SY, Jin J, Villanueva A, Michailidis E, De Jong YP, Rice CM, Marazzi I, Hasson D, Llovet JM, Sobota RM, Lujambio A, Guccione E, Dar AC. Rialdi A, et al. Among authors: lakshmanan m. Nat Cancer. 2023 Aug;4(8):1157-1175. doi: 10.1038/s43018-023-00609-9. Epub 2023 Aug 3. Nat Cancer. 2023. PMID: 37537299 Free PMC article.
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez LE, Lakshmanan M, Bethel A, Xavier D, Probstfield J, Riddle MC, Rydén L, Atisso CM, Hall S, Rao-Melacini P, Basile J, Cushman WC, Franek E, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T. Cukierman-Yaffe T, et al. Among authors: lakshmanan m. Lancet Neurol. 2020 Jul;19(7):582-590. doi: 10.1016/S1474-4422(20)30173-3. Lancet Neurol. 2020. PMID: 32562683 Clinical Trial.
Dependency of NELF-E-SLUG-KAT2B epigenetic axis in breast cancer carcinogenesis.
Zhang J, Hu Z, Chung HH, Tian Y, Lau KW, Ser Z, Lim YT, Sobota RM, Leong HF, Chen BJ, Yeo CJ, Tan SYX, Kang J, Tan DEK, Sou IF, McClurg UL, Lakshmanan M, Vaiyapuri TS, Raju A, Wong ESM, Tergaonkar V, Rajarethinam R, Pathak E, Tam WL, Tan EY, Tee WW. Zhang J, et al. Among authors: lakshmanan m. Nat Commun. 2023 Apr 28;14(1):2439. doi: 10.1038/s41467-023-38132-1. Nat Commun. 2023. PMID: 37117180 Free PMC article.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: lakshmanan m. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Dynamic altruistic cooperation within breast tumors.
Masroni MSB, Lee KW, Lee VKM, Ng SB, Law CT, Poon KS, Lee BT, Liu Z, Tan YP, Chng WL, Tucker S, Ngo LS, Yip GWC, Nga ME, Hue SSS, Putti TC, Bay BH, Lin Q, Zhou L, Hartman M, Loh TP, Lakshmanan M, Lee SY, Tergaonkar V, Chua H, Lee AVH, Yeo EYM, Li MH, Chang CF, Kee Z, Tan KM, Tan SY, Koay ES, Archetti M, Leong SM. Masroni MSB, et al. Among authors: lakshmanan m. Mol Cancer. 2023 Dec 14;22(1):206. doi: 10.1186/s12943-023-01896-7. Mol Cancer. 2023. PMID: 38093346 Free PMC article.
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Tuttle KR, et al. Among authors: lakshmanan mc. Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14. Lancet Diabetes Endocrinol. 2018. PMID: 29910024 Clinical Trial.
Role of novel histone modifications in cancer.
Shanmugam MK, Arfuso F, Arumugam S, Chinnathambi A, Jinsong B, Warrier S, Wang LZ, Kumar AP, Ahn KS, Sethi G, Lakshmanan M. Shanmugam MK, et al. Among authors: lakshmanan m. Oncotarget. 2017 Dec 17;9(13):11414-11426. doi: 10.18632/oncotarget.23356. eCollection 2018 Feb 16. Oncotarget. 2017. PMID: 29541423 Free PMC article. Review.
314 results